What side effects can be expected with bevacizumab, and which are most common and bothersome to patients? What serious side effects might occur with bevacizumab?
Bevacizumab is essentially an agent that blocks VEGF. Its toxicities are mostly related to blocking VEGF, so the way I call its toxicities is that they're mostly silent toxicities. They don't manifest themselves the way they would with chemotherapy or EGFR inhibitors, meaning the patient doesn't exhibit them per se. They're limited to hypertension, and in about 12% of patients the hypertension will require medications. You would use oral hypertensives and 99% of patients would have their blood pressure controlled this way.
Issues with wound healing, so if the patient needs emergency surgery that's something to think about. If it's an elective surgery, then you just wait 4 weeks after the last dose of bevacizumab, and some prefer 6 to 8 weeks before you do the surgery, and then you start it again 4 weeks after the surgery. There's also the risk of perforation in 1% or 2% of all patients, and that risk should stop the patient from receiving bevacizumab. There is also the risk of proteinuria, or shedding proteins through the urine, but for the overwhelming majority of the patients it's not that significant.
Unresectable Colon Cancer: Case 1
68-year-old man was diagnosed with advanced, unresectable colon cancer has just started treatment with FOLFIRI plus bevacizumab.
Retrospective Data Demonstrates Efficacy of Regorafenib in mCRC
April 16th 2024During a Case-Based Roundtable® event, Madappa Kundranda, MD, PhD, discussed recent retrospective studies that compared outcomes between the available treatment options in patients with relapsed/refractory advanced colorectal cancer in the first article of a 2-part series.
Read More
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Study Finds Susceptibility Gene Variations by Race/Ethnicity in Early-Onset CRC
February 20th 2024In an interview with Targeted Oncology, Andreana N. Holowatyj, PhD, MSCI, discussed data from a study which found racial and ethnic differences in susceptibility genes for early-onset colorectal cancer, suggesting current multigene panel tests may not be accurate for diverse populations.
Read More